Suki, a startup that makes an AI-powered and voice-enabled digital assistant for doctors, has just landed $20 million in a funding round led by Venrock, with participation from First Round, Social Capital, and Marc Benioff.
Fitbit announced yesterday that it plans to utilize Google’s new Cloud Healthcare API, in order to continue its push into the world of serious healthcare devices. It’s a bit of a no-brainer as far as partnerships go.
After a strong 2017, Sanofi Pasteur got off to a less-than-stellar start this year. In China, inspectors put a temporary kibosh on imports of the pediatric shot Pentaxim, thanks to vaccine batches that failed to pass inspection. That move hobbled the shot's sales—and dragged the rest of the unit down, too.
GlaxoSmithKline has booked a 2 percent dip in revenues for the first quarter to £7.2 billion, after results were hit by a “significant currency impact” and lower sales of prescription drugs. Profit after tax fell 38 percent to £759 million, while earnings per share dropped to 11.2p from 21.4p a year ago.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means this medicine can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms.
The name Nvidia usually creates a synapse to the video game industry — or more recently the self-driving car business. But now the computer hardware company is looking to get a foothold in the healthcare industry.
Collaboration between China's National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China - The Lilly and NCCD collaboration will address four strategic areas to advance scientific understanding and medical education related to diabetes and cardiovascular disease
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.